The UK Medicine and Healthcare Products Regulatory Agency has granted Promising Innovative Medicine (PIM) designation to Belgian drugmaker UCB’s (Euronext: UCB) zilucoplan for the treatment of adults with generalized myasthenia gravis (gMG).
Claire Brading, managing director and head of neurology UCB UK & Ireland said: “Myasthenia gravis is a serious condition that can have unpredictable and debilitating symptoms, affecting patients’ lives in multiple ways. We are pleased that zilucoplan has been recognized by the MHRA for its potential to address the urgent need for treatment innovation in this area. This is testament to UCB’s commitment to MG patients in the UK, as well as to harnessing science to bring benefit to people living with rare diseases more widely.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze